Comparison of Clinical and Angiographic Outcomes of Ranibizumab and Aflibercept in Type 1 and Aggressive Retinopathy of Prematurity
Clinical & Experimental Ophthalmology · 2025
DOI: 10.1111/ceo.14575 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical & Experimental Ophthalmology, 2025. Verfasst von Wenting Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Ranibizumab, Retinopathy of Prematurity, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The Construction Project of the "Discipline Peak-Climbing Plan" of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.
Abstract (Originalsprache)
Background
To compare the clinical and angiographic outcomes of aggressive retinopathy of prematurity (A‐ROP) and type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab (IVR) or aflibercept (IVA).
Methods
This retrospective, non‐randomised study included a consecutive series of patients with type 1 ROP or A‐ ROP who initially treated with ranibizumab (0.25 mg/0.025 mL) or aflibercept (1.0 mg/0.025 mL) between October 2017 and November 2020. Clinical data and long‐term vascular characteristics were analysed.
Results
A total of 297 eyes of 151 infants were included. Compared to IVA, IVR was a significant risk factor for reactivation in multivariate regression analysis. The risk time of reactivation in A‐ROP and Type 1 Zone I ROP was shorter in the IVR group ( p < 0.001). Fewer injections were required in the IVA group for patients with A‐ROP and Type 1 Zone I ROP ( p = 0.012). More vascular abnormalities were observed in the IVA group during reactivation, with increased arteriovenous shunting ( p = 0.028) in Type 1 Zone II ROP and more tortuosity ( p = 0.047), dilation ( p = 0.047) and plus disease ( p = 0.020) in Type 1 Zone I ROP and A‐ROP. In fundus fluorescein angiography, staining of the vessel wall and telangiectasia were more frequent in the IVA group.
Conclusions
Ranibizumab treatment was associated with a higher rate of reactivation and a shorter risk period for reactivation compared to aflibercept, potentially requiring more frequent injections, though some differences did not reach statistical significance. However, there were more signs of vascular abnormalities after receiving aflibercept treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Peiquan Zhao
Förderung
- National Natural Science Foundation of China
- The Construction Project of the "Discipline Peak-Climbing Plan" of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Zitieren
APA
Zhang, W., Ma, H., Wang, J., Chen, Z., Zhang, X., Xiao, H., Liu, H., Yang, Y., Yin, J., Wang, M., Peng, J., Xu, Y., & Zhao, P. (2025). Comparison of Clinical and Angiographic Outcomes of Ranibizumab and Aflibercept in Type 1 and Aggressive Retinopathy of Prematurity. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.14575
Vancouver
Zhang W, Ma H, Wang J, Chen Z, Zhang X, Xiao H, et al. Comparison of Clinical and Angiographic Outcomes of Ranibizumab and Aflibercept in Type 1 and Aggressive Retinopathy of Prematurity. Clinical & Experimental Ophthalmology. 2025. doi:10.1111/ceo.14575
BibTeX
@article{Zhang2025,
author = {Zhang, Wenting and Ma, Haonan and Wang, Jianhui and Chen, Zhijun and Zhang, Xuerui and Xiao, Haodong and Liu, Huanyu and Yang, Yuan and Yin, Jiawei and Wang, Mingyang and Peng, Jie and Xu, Yu and Zhao, Peiquan},
title = {Comparison of Clinical and Angiographic Outcomes of Ranibizumab and Aflibercept in Type 1 and Aggressive Retinopathy of Prematurity},
journal = {Clinical & Experimental Ophthalmology},
year = {2025},
doi = {10.1111/ceo.14575}
}
EUVIMED